Spyre Therapeutics' one-year price target was raised to $88.06 per share from $62.00, a 42.03% increase from the April 12, 2026 estimate. The update reflects a materially more positive analyst outlook for the biotech name. This is a sentiment-positive revision, but it is routine analyst commentary rather than a broader market-moving event.
Spyre Therapeutics' one-year price target was raised to $88.06 per share from $62.00, a 42.03% increase from the April 12, 2026 estimate. The update reflects a materially more positive analyst outlook for the biotech name. This is a sentiment-positive revision, but it is routine analyst commentary rather than a broader market-moving event.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
